Resveratrol for Post-COVID-19 Cognitive Dysfunction: From Molecular Basis to Clinical Translation
- 1Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Universidad Autónoma de Zacatecas, Zacatecas-Guadalajara km. 6, Ejido La Escondida, Zacatecas 98160, Mexico
- 2Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Av. Eugenio Garza Sada 2501, Monterrey 64849, Mexico
Abstract
Post-COVID-19 condition can include persistent cognitive symptoms, commonly described as impaired attention, memory difficulties, slowed processing, and “brain fog.” Clinical and translational evidence implicates systemic inflammation, neurovascular dysfunction, blood–brain barrier disruption, glial inflammatory responses, oxidative stress, and altered synaptic or network function; their relative contributions remain uncertain and may differ across patient subgroups. Resveratrol is a polyphenolic compound that modifies inflammatory, redox, metabolic, endothelial, and antiviral pathways in experimental systems. This focused narrative review examines whether those actions provide a mechanistic basis for the use of resveratrol in post-COVID-19 cognitive dysfunction. Evidence was considered according to biological proximity to the intended indication, distinguishing human post-acute sequelae of SARS-CoV-2 infection (PASC) studies from acute-COVID-19, non-COVID-19 clinical, animal, organoid, and cell-based evidence. The review identifies candidate neurovascular, immune, and metabolic processes, evaluates where resveratrol evidence intersects with those processes, and distinguishes molecular observations from clinical questions that remain to be tested for to define the therapeutic potential of using resveratrol to treat post-COVID-19 cognitive impairment.
Related
- Omics-derived signatures in metabolic dysfunction-associated steatotic liver disease: from molecular characterization to clinical translation.
- Omics-based Decoding of Metabolic Dysfunction-associated Fatty Liver Disease: From Pathogenesis to Clinical Translation
- Executive dysfunction in COPD: prevalence and clinical correlates of cognitive impairment : A cross-sectional case–control study
- Extracellular vesicles in vascular cognitive impairment and dementia: a neurovascular evidence map for patient stratification and clinical translation
- Updating deficits in subjective cognitive decline: A differential pattern of executive dysfunction across clinical stages.
BibTeX
@article{martinezfierro2026resveratrol,
title = {{Resveratrol for Post-COVID-19 Cognitive Dysfunction: From Molecular Basis to Clinical Translation}},
author = {Margarita L. Martinez-Fierro and Samantha Gonzalez-Delgado and Israel A. Solis-Hernandez and Maria del R. Rocha-Pizaña and Ana J. Mendez-Gonzalez and Idalia Garza-Veloz},
journal = {Molecules},
year = {2026},
month = oct,
doi = {10.3390/molecules31203747},
url = {https://www.mdpi.com/1420-3049/31/20/3747},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Resveratrol for Post-COVID-19 Cognitive Dysfunction: From Molecular Basis to Clinical Translation
AU - Margarita L. Martinez-Fierro
AU - Samantha Gonzalez-Delgado
AU - Israel A. Solis-Hernandez
AU - Maria del R. Rocha-Pizaña
AU - Ana J. Mendez-Gonzalez
AU - Idalia Garza-Veloz
PY - 2026
DA - 2026/10/01
JO - Molecules
DO - 10.3390/molecules31203747
UR - https://www.mdpi.com/1420-3049/31/20/3747
AB - Post-COVID-19 condition can include persistent cognitive symptoms, commonly described as impaired attention, memory difficulties, slowed processing, and “brain fog.” Clinical and translational evidence implicates systemic inflammation, neurovascular dysfunction, blood–brain barrier disruption, glial inflammatory responses, oxidative stress, and altered synaptic or network function; their relative contributions remain uncertain and may differ across patient subgroups. Resveratrol is a polyphenolic compound that modifies inflammatory, redox, metabolic, endothelial, and antiviral pathways in experimental systems. This focused narrative review examines whether those actions provide a mechanistic basis for the use of resveratrol in post-COVID-19 cognitive dysfunction. Evidence was considered according to biological proximity to the intended indication, distinguishing human post-acute sequelae of SARS-CoV-2 infection (PASC) studies from acute-COVID-19, non-COVID-19 clinical, animal, organoid, and cell-based evidence. The review identifies candidate neurovascular, immune, and metabolic processes, evaluates where resveratrol evidence intersects with those processes, and distinguishes molecular observations from clinical questions that remain to be tested for to define the therapeutic potential of using resveratrol to treat post-COVID-19 cognitive impairment.
SN - 1420-3049
ER -